Treat to target in systemic lupus erythematosus: a commentary
- 12 July 2016
- journal article
- review article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 35 (8) , 1903-1907
Abstract
Treat to target (T2T) strategies have proved to be useful in several chronic disorders, including Rheumatoid Arthritis. In systemic lupus erythematosus (SLE), T2T strategy has been proposed in order to control disease activity, improve health-related quality of life, and reduce morbidity and mortality. Remission would be the main target, but a low disease activity state (LDAS) could be an acceptable alternative. However, due to SLE protean manifestations, the operational definitions of both remission and LDAS are still in progress. The definitions of these targets, remission and LDAS, should include a validated disease activity index, the treatments allowed, and the minimum length of time the target should be maintained. Furthermore, achieving these targets should result in better disease outcomes such as reducing damage accrual. This review addresses the current state regarding these possible targets in SLE and the impact of achieving them in intermediate and long-term outcomes of this disease.Keywords
This publication has 22 references indexed in Scilit:
- Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?Arthritis & Rheumatology, 2013
- Treat‐to‐target trials: uses, interpretation and review of conceptsDiabetes, Obesity and Metabolism, 2013
- Global trends, potential mechanisms and early detection of organ damage in SLENature Reviews Rheumatology, 2012
- Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent periodArthritis Care & Research, 2011
- The effect of moderate‐dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2006
- Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trialArthritis & Rheumatism, 2005
- High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosusRheumatology, 1999
- Remission of Systemic Lupus ErythematosusMedicine, 1996
- Prevention of relapses in systemic lupus erythematosusThe Lancet, 1995
- Prolonged complete remission in previously severe SLE.Annals of the Rheumatic Diseases, 1982